Document:

Tonix Pharmaceuticals Holding Corp. 10-Q

Exhibit 10.03

SOS-079 ·CHU
AMENDMENT 3/25/2020 AMENDMENT .NI!2 TO THE EXCLUSIVE LICENSE AGREEMENT (AMENDED AND RESTATED) EFFECTIVE THE 30TH DAY
OF NOVEMBER 2007 BETWEEN STANFORD UNIVERSITY AND TRIGEMINA, INC. Effective the 26th day ofMarch2020, THE BOARD OF TRUSTEES
OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the
laws of the State of California, and Trigemina, Inc. (“Trigemina”), a corporation having a principal place of business
at 1036 Country Club Drive, Suite 200, Moraga, CA 94556, agree as follows: 1. BACKGROUND Stanford and Trigemina are parties
to a License Agreement effective the 30th day of November 2007 (“Original Agreement”) covering “Therapy Procedure
for Cranial Pain Syndromes,” disclosed in Stanford Docket S05-079 from the laboratory of Dr. Dave Yeomans and jointly owned
with HealthPartners Research Foundation (HPRF) and disclosed in HPRF Docket 200507. The Original Agreement was amended by an Amendment
No.1 effective November 10,2015 to delay the due date for payment of the License Maintenance Fees due from 2009 through 2015.
Stanford and Trigemina wish to amend the Original Agreement (“Amendment No.2”) to set dates by which to pay in full
all unpaid License Maintenance Fees and to defme future due diligence milestones. 2. AMENDMENT 2.1 Amendment Fee.
Within 30 days after execution of this Amendment No. 2, Trigemina will pay to Stanford an amendment fee of$2,000. 2.2 Licensed
Maintenance Fees. Within 30 days after execution of this Amendment No.2, Trigemina will pay to Stanford the total due on License
Maintenance Fees as detailed in Appendix 1. Notwithstanding the foregoing, Trigemina is still obligated to pay the License Maintenance
Fees as detailed in Sections 6.2(B) and 6.2(C) of the Original Agreement.

 

     

     

    

 

Appendix A of the
Original Agreement and will include, but not be limited to, the projected date of filing a new drug application (NDA) with the
FDA and first commercial sale of a Licensed Product. 3. OTHER TERMS 3.1 All other terms of the Original Agreement remain in full
force and effect. 3.2 The parties to this document agree that a copy of the original signature (including an electronic copy)
may be used for any and all purposes for which the original signature may have been used. The parties further waive any right
to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature.
The parties execute this Amendment No. 2 by their duly authorized officers or representatives. TM BOARD OF TRUSTEES OF THE LELAND
STANFORD JUNIOR UNIVERSITY Signature: Name: Title: Date: Mona Wan Associate Director Mar 30, 2020 Mona Wan (Mar 30, 020) TRIGEMINA
INC. PAGE 2 OF 3

 

     

     

    

 

SOS-079 ·CHU
AMENDMENT 3/25/2020 Appendix 1 Year License Maintenance Fee Past Due Invoice Number 2009 $10,000 57911 2010 $10,000 61393
2011 $15,000 55061 2012 $15,000 68610 2013 $15,000 72283 2014 $15,000 75924 2015 $15,000 79842 2016 $15,000 84070 2017 $15,000
88744 2018 $15,000 93403 2019 $15,000 98384 Total $155,000Tonix Pharmaceuticals Holding Corp. 10-Q

Exhibit 10.04

 

assignment
and ASSUMPTION AGREEEMENT and Amendment No. 3 to

 

the
exclusive license (amended and restated) Agreement

 

This
Assignment and Assumption Agreement and Amendment No. 3 to the Exclusive License (Amended and Restated) (“Agreement”),
entered into as of June 11, 2020 (“Effective Date”), is made by and among The Board of Trustees of the Leland
Stanford Junior University, ("Stanford"), an institution of higher education having powers under the laws of
the State of California; Trigemina, Inc. ("Trigemina"), a corporation having a principal place of business at
1036 Country Club Drive, Suite 200, Moraga, California 94556; and Tonix Pharmaceuticals, Inc., a corporation having a principal
place of business at 509 Madison Avenue, Suite 306, New York, NY 10022 (“Tonix” and, together with Trigemina
and Stanford, the “Parties”, and each of Tonix, Trigemina, and Stanford, a “Party”).

 

WITNESSETH:

 

WHEREAS,
Trigemina and Stanford entered into that certain Exclusive License (Amended and Restated) dated November 30, 2007, as amended
by Amendment No. 1 dated November 10, 2015 and Amendment No. 2 dated March 26, 2020 (the “License Agreement”);

 

WHEREAS,
Trigemina Holdings, Inc. (“Trigemina Holdings”) and Tonix have entered into an Asset Purchase Agreement dated
June 11, 2020 (“APA”), pursuant to which Trigemina Holdings has agreed to assign the License Agreement in full,
including all rights and obligations thereunder, to Tonix and Tonix has agreed to accept such assignment of rights and agrees
to assume such obligations;

 

WHEREAS,
there are certain past due amounts owed by Trigemina to Stanford under the License Agreement that Tonix has agreed to pay as part
of the consideration under the APA; and

 

WHEREAS,
Stanford and Tonix wish to make certain amendments and modifications to the License Agreement as set forth herein.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby
agree as follows:

 

AGREEMENT

 

Section
1. Defined Terms. Capitalized terms not
defined in this Agreement shall have the respective meaning set forth in the License Agreement, unless otherwise stated.

 

Section
2. Assignment and Assumption.

 

(a)       Trigemina
hereby assigns, transfers, and conveys to Tonix all of Trigemina’s rights and obligations under the License Agreement, and
Tonix accepts and assumes from Trigemina such assignment, transfer, and conveyance. As of the Effective Date, Tonix shall be deemed
a Party to the License Agreement substituted in the place of Trigemina, and Tonix will benefit from all of the rights of, and
shall be bound by and perform all of the obligations, representations, covenants and warranties of Trigemina under the License
Agreement as if Tonix were originally named in place of Trigemina in the License Agreement.

 

     

     

    

 

(b)       In
connection with the assignment and assumption of the License Agreement by Tonix, Tonix shall pay to Stanford the Seventy-Five
Thousand Dollar ($75,000) assignment fee required under the License Agreement within ten (10) days of the Effective Date.

 

(c)       Stanford
hereby acknowledges and agrees that this Section 2 satisfies any and all requirements in Section 14.3 of the License Agreement
regarding the assignment and assumption of the License Agreement by Tonix.

 

SECTION
3. Outstanding License Agreement Payments. Within ten (10) days of the Effective Date, Tonix shall pay to Stanford One
Hundred Seventy-Five Thousand Two Hundred Forty-One Dollars ($175,241) in satisfaction of all outstanding or accrued unpaid payment
obligations under the License Agreement as of the Effective Date, including the amendment fees, maintenance fees and past patent
costs set forth in Amendment No. 2.

 

SECTION
4. Amendments to the License Agreement.

 

(a)       The
Parties agree to amend the License Agreement as follows:

 

 (i)          Section
6.3(A) of the License Agreement shall be amended and replaced in its entirety as follows:

 

“(A)
$125,000 upon Trigemina's filing of the first Investigational New Drug application for a Phase III clinical trial of the Licensed
Product;”.

 

(ii)        Milestone
3 of Appendix A of the License Agreement shall be deleted in its entirety and replaced by the following:

 

“By
July 1, 2021 Trigemina will meet with Stanford to discuss further diligence milestones based on Trigemina’s business plans
and industry standards for the development and commercialization of the Licensed Product. Such diligence milestones will be attached
to Appendix A to the License Agreement and will included, but not limited to, the projected date of filing a new drug application
(NDA) with the FDA and first commercial sale of the Licensed Product.”

 

(b)       The
Parties agree that, except as explicitly stated herein, all of the terms and conditions of the License Agreement, remain unchanged
and in full force and effect.

 

SECTION
9. Miscellaneous.

 

(a)       Waiver.
No term of this Agreement can be waived except by the written consent of the Party waiving compliance.

 

(b)       Transaction
Expenses. Each Party is responsible for its own legal, accounting and other transaction costs.

 

    -2- 

     

    

 

(c)       Choice
of Law. This Agreement and any dispute arising under it is governed by the laws of the State of California United States of
America applicable to agreements negotiated, executed, and performed within California.

 

(d)       Exclusive
Forum. The state and federal courts having jurisdiction over Stanford, California, United States of America provide the exclusive
forum for any court action between the Parties relating to this Agreement. Trigemina and Tonix submit to the jurisdiction of such
courts, and waive any claim that such a court lacks jurisdiction over Trigemina or Tonix or constitutes an inconvenient or improper
forum.

 

(e)       Headings.
No headings in this Agreement affect its interpretation.

 

(f)       Electronic
Copy. The Parties to this document agree that a copy of the original signature (including an electronic copy) may be used
for any and all purposes for which the original signature may have been used. The Parties further waive any right to challenge
the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature.

 

(g)       Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together
shall constitute a single instrument.

 

[Signature
page follows]

 

    -3- 

     

    

 

IN
WITNESS WHEREOF, this Agreement is executed as of the date first written above on behalf of the Parties by their duly authorized
representatives.

  

	TONIX PHARMACEUTICALS, INC.	 	TRIGEMINA, INC.
	 	 	 	 	 
	By:	                           
	 	By:	                     
	 	 
	 	 	 	 	 	 	 
	Name:  Seth Lederman,
    M.D.	 	Name:  Michael Scaife	 	 
	 	 	 	 	 
	Title:  Chief Executive
    Officer	 	Title:  Chief Executive
    Officer	 	 

  

The
Board of Trustees of the 

Leland
Stanford Junior University

  

	By:	                       	           

 

Name:

 

Title:

 

    -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]